Abdulla A. Damluji, MD, PhD
Abdulla A. Damluji, MD, PhD

@DrDamluji

11 Tweets 18 reads Nov 13, 2023
Great #AHA23 so far: @AHA_Research
🥸8 Trials: 8 take aways below
Read the read👇👇
1/ATRESIA:
Patients with subclinical atrial fibrillation can benefit from apixaban to reduce the risk of stroke and systemic thromboembolism.
2/CARDIA-SSBP:
🥸The decline in SBP with a low-sodium diet was independent of hypertension status and anti-hypertensive medication use, consistent across subgroups, and did not result in excess adverse
3/ CRHCP:
🥸Intensive BP lowering (target BP < 130/80 mm Hg) significantly reduced risk of all-cause dementia among patients with hypertension, supporting the use of intensive hypertension treatment to reduce the burden of dementia.
😱 @cardskrish
4/ KARDIA-1
🥸 Single doses of subcutaneous zilebesiran were effective in reducing blood pressure in adults with mild-to-moderate hypertension for up to 6 months!
5/ MINT:
🥸 A liberal transfusion strategy has the potential for clinical benefit with low risk in anemic patients with
MI.
😱 No difference in primary outcome between liberal and conservative strategies.
6/ORBITA-2
PCI outperformed a placebo procedure for people with minimal anti-anginal medication enhancing chest pain relief, exercise ability, and overall quality of life!
😱PCI works: @JAMAInternalMed
7/POP-HT
🥸 Optimization of blood pressure during the immediate postpartum period resulted in lower blood pressure throughout the first-year postpartum!
8/ SELECT
🥸Weekly addition of subcutaneous semaglutide to standard of care improved cardiovascular outcomes in patients with pre-exiting cardiovascular disease and overweight or obese, but without diabetes.
😱 This one will have incredible impact!
** Sorry for typo: meant "read the thread"
9/Heart-1
🥸 Single course gene editing medicine could emerge as a game changer in treating elevated LDL-levels.
#VERVTherapeutics

Loading suggestions...